Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammed Saad

Internal Medicine Mount Jackson, VA Medical Doctor

NPI 1063854586 CMS profile 6367920

120 Medical Dr, Mount Jackson, VA 22842

Open in the dashboard

General payments

$8,108

404 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammed Saad of Mount Jackson, VA is reported in the CMS Open Payments database as having received $8,108 across 404 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $337 10
2024 General $857 18
2023 General $524 23
2022 General $2,712 146
2021 General $2,110 110
2020 General $1,063 67
2019 General $504 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammed Saad
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mohammed Saad were reported at $337. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mohammed Saad Internal Medicine median Middle half National median
2019 $504 $159 $48–$570 $163
2020 $1,063 $119 $33–$402 $114
2021 $2,110 $135 $37–$521 $132
2022 $2,712 $141 $42–$496 $149
2023 $524 $149 $45–$519 $160
2024 $857 $154 $47–$537 $164
2025 $337 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $1,008 55 payments
  2. AstraZeneca Pharmaceuticals LP $736 38 payments
  3. Pfizer Inc. $508 34 payments
  4. Novartis Pharmaceuticals Corporation $459 24 payments
  5. Incyte Corporation $443 19 payments
  6. Lilly USA, LLC $407 21 payments
  7. Genentech USA, Inc. $308 17 payments
  8. Amgen Inc. $303 19 payments
  9. Pharmacyclics LLC, An AbbVie Company $299 16 payments
  10. E.R. Squibb & Sons, L.L.C. $284 18 payments
  11. Other $3,352 143 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,060 391 payments
  2. Education $1,048 13 payments
Products named General payments · program years 2019–2025
  1. DARZALEX $542 40 payments
  2. IMBRUVICA $440 39 payments
  3. ERLEADA $399 9 payments
  4. JEVTANA $379 12 payments
  5. RETEVMO $356 19 payments
  6. JAKAFI $343 18 payments
  7. VERZENIO $324 16 payments
  8. Lenvima $284 10 payments
  9. TAGRISSO $254 14 payments
  10. XTANDI $248 14 payments
  11. Other $7,006 383 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

1,152

Median for Internal Medicine: 777

Drug cost

$82,009

Median for Internal Medicine: $73,373

Branded share of claims

18.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 60 $45,244
Januvia Sitagliptin Phosphate Brand 27 $23,590
Albuterol Sulfate Hfa Albuterol Sulfate Brand 34 $1,208
Esomeprazole Magnesium Generic 11 $1,002
Pantoprazole Sodium Generic 47 $847
Synthroid Levothyroxine Sodium Brand 12 $693
Atorvastatin Calcium Generic 80 $652
Metoprolol Succinate Generic 39 $517
Diclofenac Sodium Generic 14 $498
Paroxetine Hcl Generic 27 $478

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$74,989

Of which drugs: $3,302

Medicare patients

337

Average age 74

Services billed

901

153 women, 184 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Chronic kidney disease 43%
Diabetes 39%
Ischemic heart disease 36%
Cancer 30%
Heart failure 28%
Atrial fibrillation 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 11 11 $3,149

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Lenvima
  • Eisai Inc. $130
$130 — —
ENHERTU
  • Daiichi Sankyo Inc. $125
$125 — —
PYLARIFY
  • Progenics Pharmaceuticals, Inc. $125
$125 — —
ERLEADA
  • Janssen Biotech, Inc. $124
$124 — —
ALUNBRIG
  • Takeda Pharmaceuticals U.S.A., Inc. $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

404 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record